ClinicalTrials.Veeva

Menu

A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia

Allergan logo

Allergan

Status and phase

Completed
Phase 2

Conditions

Postherpetic Neuralgia

Treatments

Drug: Botulinum Toxin Type A

Study type

Interventional

Funder types

Industry

Identifiers

NCT00168441
191622-066

Details and patient eligibility

About

4-month study including a 30-day baseline phase

Enrollment

117 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.

Exclusion criteria

  • Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems